Get new exclusive access to healthcare business reports & breaking news
In this episode, Codrin Arsene is joined by Kevin Costa. He is the Co-Founder and Chief Scientific Officer of Novoheart, a company that creates three-dimensional heart constructs which drug manufacturers can use to test out various drugs and treatments.
The current drug development process can take ten years or more to complete. Kevin describes this very inefficient process and the costs incurred by manufacturers.
He talks about the inaccurate results that testing animals provides and Novoheart’s offering of a much more reliable solution.
The potential impact on medicine and healthcare by developing heart constructs that are specific to an individual patient is enormous.
Kevin says that right now the costs may be prohibitive but explains that it is completely doable.
Subscribe to‘Healthcare Weekly: At the Forefront of Healthcare Innovation’ podcast on your favorite podcast network, today! New episodes released every week.
Love this podcast? Check out these other recent episodes:
You may also be interested in reading about: A Robot That Can Fix Hearts Autonomously Is Here